Publications by authors named "Hitoshi Hanamoto"

Claim this Profile
A
Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells.
Aki Fujii-Hanamoto, Hirokazu Tanaka, Ko Fujimoto, Takahiro Haeno, Yoshiaki Miyake, Hitoshi Hanamoto

Curr Issues Mol Biol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD34 and CD34 MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34 MM cells.
Ayano Fukui-Morimoto, Kentaro Serizawa, Ko Fujimoto, Aki Hanamoto, Yoshio Iwata, Hitoshi Hanamoto

Int J Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Naokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, Satoshi Yoshioka, Kazunori Imada, Hitoshi Hanamoto

Ann Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Hitoshi Hanamoto

Cancer Immunol Immunother· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.
Yuji Shimura, Hirohiko Shibayama, Aya Nakaya, Ryosuke Yamamura, Kazunori Imada, Hitoshi Hanamoto

Int J Hematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.
Aya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, Ryosuke Yamamura, Satoshi Yoshioka, Hitoshi Hanamoto

Leuk Res Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia responding to retreatment with inotuzumab ozogamicin].
Hiroshi Hashimoto, Yuhei Tamura, Kaori Yamada, Yuriko Katoh, Takahiro Shimada, Hitoshi Hanamoto

Rinsho Ketsueki· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.
Yutaka Shimazu, Junya Kanda, Satoru Kosugi, Tomoki Ito, Hitomi Kaneko, Hitoshi Hanamoto

Sci Rep· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monocyte or white blood cell counts and β microglobulin predict the durable efficacy of daratumumab with lenalidomide.
Yutaka Shimazu, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Ryosuke Yamamura, Hitoshi Hanamoto

Ther Adv Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.
Yasuyoshi Morita, Yasuhito Nannya, Motoshi Ichikawa, Hitoshi Hanamoto, Hirohiko Shibayama

Int J Hematol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
Ryosuke Fujiwara, Yasuhiro Taniguchi, Shinya Rai, Yoshio Iwata, Aki Fujii, Hitoshi Hanamoto

Biochem Biophys Res Commun· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-Ichi Fuchida, Hitoshi Hanamoto

Ther Adv Hematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Shinya Rai, Hiroaki Inoue, Kazuko Sakai, Hitoshi Hanamoto, Mitsuhiro Matsuda

Cancer Sci· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.
Yuichiro Hamamoto, Yoji Kukita, Masanori Kitamura, Masako Kurashige, Hiroaki Masaie, Hitoshi Hanamoto

Histopathology· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synchronous gastric cancer and primary lymphoma of right adrenal gland: a case report.
Shuichi Fukuda, Tomoko Wakasa, Hitoshi Hanamoto, Taichi Koyama, Yoshio Ohta

Clin J Gastroenterol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial.
Shinya Rai, Hiroaki Inoue, Hitoshi Hanamoto, Mitsuhiro Matsuda, Yasuhiro Maeda

Int J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
Masaaki Hotta, Atsushi Satake, Hideaki Yoshimura, Shinya Fujita, Yuta Katayama, Hitoshi Hanamoto

Transplant Cell Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Teruhito Takakuwa, Ryosuke Yamamura, Kensuke Ohta, Hitomi Kaneko, Kazunori Imada, Hitoshi Hanamoto

Eur J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occult follicular lymphoma in a swollen regional lymph node of gastric schwannoma.
Shuichi Fukuda, Taichi Koyama, Tomoko Wakasa, Hitoshi Hanamoto, Tomoyuki Tsujimoto

Surg Case Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolated myeloid sarcoma presenting with small bowel obstruction: a case report.
Rie Mizumoto, Masanori Tsujie, Tomoko Wakasa, Kotaro Kitani, Hironobu Manabe, Hitoshi Hanamoto

Surg Case Rep· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Yasuyoshi Morita, Yasuhiro Maeda, Terufumi Yamaguchi, Fumiaki Urase, Shuhei Kawata, Hitoshi Hanamoto

Cancer Sci· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
Yasuhiro Taniguchi, Hirokazu Tanaka, Espinoza J Luis, Kazuko Sakai, Takahiro Kumode, Hitoshi Hanamoto

Int J Hematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choroidal metastasis from granulocyte colony-stimulating factor-producing esophageal squamous cell carcinoma: a case report.
Shuichi Fukuda, Yoshinori Fujiwara, Hiroshi Mishima, Tomoko Wakasa, Hitoshi Hanamoto

Clin Case Rep· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of an elderly frail patient with acquired idiopathic thrombotic thrombocytopenic purpura under close monitoring of ADAMTS13 activity and anti-ADAMTS13 antibody titers.
Keigo Sano, Hideo Yagi, Hitoshi Hanamoto, Mariko Fujita, Takashi Iizuka

Transfus Apher Sci· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Epstein-Barr virus infection in adult T-cell leukemia.
Satomi Ueda, Yasuhiro Maeda, Terufumi Yamaguchi, Hitoshi Hanamoto, Yasuki Hijikata

Hematology· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis